Clinical Trial Update: Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic drug-drug interaction study evaluating encorafenib and binimetinib on probe drugs in patients with BRAF V600-mutant melanoma or other ad…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Solid Tumor

Drugs mentioned

• BRAFTOVI (ENCORAFENIB)
• MEKTOVI (BINIMETINIB)

Snippet

Sponsor: Pfizer | Conditions: Advanced Solid Tumors, Metastatic Melanoma | Phase 1 | Status: COMPLETED | Results posted: 2024-09-27